Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S; TEMPO Study Investigators. van der Heijde D, et al. Among authors: klareskog l. Arthritis Rheum. 2006 Apr;54(4):1063-74. doi: 10.1002/art.21655. Arthritis Rheum. 2006. PMID: 16572441 Free article. Clinical Trial.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Klareskog L, et al. Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7. Lancet. 2004. PMID: 15001324 Clinical Trial.
Rheumatoid arthritis and malignant lymphomas.
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Baecklund E, et al. Among authors: klareskog l. Curr Opin Rheumatol. 2004 May;16(3):254-61. doi: 10.1097/00002281-200405000-00014. Curr Opin Rheumatol. 2004. PMID: 15103253 Review.
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK. Catrina AI, et al. Among authors: klareskog l. Arthritis Rheum. 2005 Jan;52(1):61-72. doi: 10.1002/art.20764. Arthritis Rheum. 2005. PMID: 15641091 Free article. Clinical Trial.
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. Askling J, et al. Among authors: klareskog l. Arthritis Rheum. 2005 Jul;52(7):1986-92. doi: 10.1002/art.21137. Arthritis Rheum. 2005. PMID: 15986370 Free article.
A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination.
Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. Klareskog L, et al. Arthritis Rheum. 2006 Jan;54(1):38-46. doi: 10.1002/art.21575. Arthritis Rheum. 2006. PMID: 16385494 Free article.
730 results